Idt Australia Limited · ASX:IDT
Idt Australia — Investor Presentation (June 2015)
14 slides from Idt Australia's investor presentation, Jun 1, 2015
Slide 1: Safe Harbour
6/1/2015 For personal use only SAFE HARBOUR This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of IDT Australia Ltd to be materially differen
Slide 2: Investment Proposition
6/1/2015 IDT AUSTRALIA LTD INVESTMENT PROPOSITION For personal use only The Business Portfolio of 23 US FDA approved generic drugs Contract drug development Contract drug manufacturing Drug development services incl. clinical trials High tech 12,000m2 facility in Boronia VIC. Replacement value ~$75m
Slide 3: IDT Portfolio Growth: 23 US Generic Drugs
6/1/2015 IDT PORTFOLIO GROWTH 23 US GENERIC DRUGS For personal use only • Purchased Nov2014, now being moved into IDT facility and first batches manufactured • Therapeutic areas incl. – Neurology – Infectious diseases – Cardiovascular – Respiratory • Addressable market of $US460m (IMS*) • Rapid path
Slide 4: New Products cont. / US Market Re-entry Process
6/1/2015 NEW PRODUCTS cont. For personal use only Product Dose Form Indication Class Flecainide Tablet Tachycardia Cardiovascular Fluconazole Tablet Infectious Disease Infectious Disease Leucovorin Tablet Methotrexate Antidote Oncology Methoxsalen Capsule Vitilago Dermatology Mexiletine Capsule Arrh
Slide 5: Path to Market / Value Creation
6/1/2015 PATH TO MARKET IDT US DISTRIBUTOR APPOINTMENTS For personal use only • Temozolomide distribution secured in the US, equitable gross margin split (US$300 US addressable market) • US distributor for purchased ANDA products: – Strong competition for the assets, 12 distribution term sheets rece
Slide 6: Effect of Operational Leverage / Recent Comparable Transactions
6/1/2015 EFFECT OF OPERATIONAL LEVERAGE For personal use only SCENARIO: Organic growth + product registrations Revenue Growth Rate Profit Growth Rate BREAKEVEN Year 1 Year 2 Year 3 Year 4 www.idtaus.com.au 11 RECENT COMPARABLE TRANSACTIONS • ANI Pharma purchase of 31 generic assets Nov 2013 – Was to
Slide 7: Developing Our Own Speciality Generics
6/1/2015 DEVELOPING OUR OWN SPECIALITY GENERICS For personal use only $$ MARGIN WITHIN VALUE CHAIN IDT REGISTRATION & SUPPLY DISTRIBUTOR IDT’s current 2% margin share WHOLESALER Available margin up to 50 - 60% Example: PROJECT TETON: IDT currently the dominant supplier of active pharmaceutical ingre
Slide 8: Our Customers Are World Leaders
6/1/2015 OUR CUSTOMERS ARE WORLD LEADERS For personal use only www.idtaus.com.au 15 CREATING WORLD LEADING PRODUCTS SENSITIZING DRUGS ANTI–CANCER DRUGS HORMONES CARBOHYDRATE DRUGS HIGH CONTAINMENT TABS/CAPS HIGH CONTAINMENT TAB COATING www.idtaus.com.au 16 8
Slide 9: Medicines Made in Our Melbourne Facility
6/1/2015 MEDICINES MADE IN OUR MELBOURNE FACILITY For personal use only $75m advanced manufacturing facility 12,000m2 state-of-the-art Current 10-15% capacity utilisation Large scope for growth without need for material increases in: CAPEX, or site support costs Ability to manufacture from gram to t
Slide 10: A Prescription for Growth: Move from Making to Marketing
6/1/2015 For personal use only A PRESCRIPTION FOR GROWTH MOVE FROM MAKING TO MARKETING www.idtaus.com.au 20 10
Slide 11: Good Medicine & Higher Returns for IDT
6/1/2015 GOOD MEDICINE & HIGHER RETURNS FOR IDT For personal use only SELL MORE EXISTING PRODUCTS EXTRACT MORE PROFITS • High fixed costs = operational leverage. • Extract more profits from those products to improve • As a result, profits will rise faster than revenues past our share of the value ch
Slide 12: Board & Management; Financially Positioned to Deliver
6/1/2015 BOARD & MANAGEMENT IN PLACE TO DELIVER For personal use only MANAGEMENT TEAM BOARD Dr Paul D R MacLeman (CEO & MD) Graeme Kaufman (Chairman) Deb Cailes (Market Access) Dr Paul D R MacLeman (MD) Jane Kelly (Clinical) Geoff Lord (Vice Chairman) Joanna Johnson (CFO) Dr Graeme Blackman (NED) St
Slide 13: Target 2015 Milestones
6/1/2015 TARGET 2015 MILESTONES For personal use only INCREASED 2014/15 ORGANIC SALES GROWTH MOVEMENT OF AN ADDITIONAL INTERNAL PRODUCT TOWARDS MARKET PROGRESS WITH RE-COMMERCIALISATION OF 23 ACQUIRED US PRODUCTS MOVE FROM SERVICE PROVIDER, TOWARDS SPECIALTY GENERIC PHARMACEUTICAL COMPANY, GROWTH &
Slide 14: Questions and Answers
6/1/2015 For personal use only QUESTIONS AND ANSWERS 14